2m 2m 2m 2m 2m 2m 2m
- $182.8MMarket Cap
- -11.37%1-Year Change
- Medical Instruments & SuppliesIndustry
STEREOTAXIS (STXS)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 22
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Stereotaxis Eyes Billions In Market Opportunity With Robocath Takeover
Stereotaxis announced a definitive agreement to acquire Robocath, a developer of robotic technologies for interventional cardiology and neurointerventions. The acquisition is expected to contribute approximately $2 million in annual revenue in the first year and reach breakeven by year three. The deal includes a $20 million upfront payment with up to $25 million in contingent payments tied to regulatory and commercial milestones, with closing expected in mid-2026. Stereotaxis plans to pursue regulatory submissions in the US and Europe within two years and expand into electrophysiology applications.
04/15/2026, 1:02 PM • Benzinga
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
Stereotaxis announced it will release its 2025 fourth quarter and full year financial results on March 9, 2026, followed by a conference call at 4:30 p.m. ET to discuss results and corporate developments. The company is a leader in surgical robotics for minimally invasive endovascular intervention.
02/12/2026, 9:00 AM • GlobeNewswire
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
Stereotaxis will release its Q3 2025 financial results on November 11, 2025, and host a conference call at 4:30 p.m. ET to discuss company results and developments.
10/21/2025, 9:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Key Executives
- Kimberly R. Peery
- David Leo Fischel
- Patricia S. Williams
- Keith Galloway
Current Ownership Distribution
- Institutions741.2M (85.80%)
- Mutual Funds96.3M (11.14%)
- Insiders26.4M (3.05%)
- Other0 (0.00%)